October 1, 2025
Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer
Read moreTogether,
we can reach
higher ground
At Climb Bio, it is our mission to deliver high impact, disease-modifying medicines for individuals living with immune-mediated diseases.
October 1, 2025
Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer
Read moreScaling new heights in the development of transformative immune medicines
We all only have one life to live. At Climb, we all feel the urgency to give everyone living with an immune-mediated disease more quality time—and less time thinking of themselves as a patient.
Scientific approach
We develop differentiated monoclonal antibodies for immune-mediated diseases.
Pipeline
Our investigational therapies have the potential to address immune-mediated diseases impacting patients with limited therapeutic options.
Clinical trials
We are advancing clinical studies across multiple disease areas to evaluate the potential of our investigational therapies to improve clinical outcomes for patients.
Patient stories
Behind every condition is a person with a unique journey. Learn more about the lived experiences of patients who inspire our work and drive our commitment to developing new therapies.
Learn more
Come climb with us
Here you’ll find good people. Smart people. Curious people. Our team has a diversified past, a singular focus on the now, and an unshakeable commitment to a better future.